Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A Thromb Hoemosr. 2017;117(2):252-261.
Esperoct® - Especialidad Medicinal autorizada por el Ministerio de Salud. Certificado N 59.382. Prospecto vigente aprobado por ANMAT (ver código QR)
Giangrande P, Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2.J Thromb Haemost. 2020:18(1 ):5-14.
Esperoct® - Especialidad Medicinal autorizada por el Ministerio de Salud. Certificado N 59.382. Prospecto vigente aprobado por ANMAT (ver código QR).
Hampton K, Chowdary P, Dunkley S, et al. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. Haemophilia. 2017; 23(5):689-696
Esperoct® - Especialidad Medicinal autorizada por el Ministerio de Salud. Certificado N 59.382. Prospecto vigente aprobado por ANMAT (ver código QR).
Giangrande P. Andreeva T. Chowdacy P. et al. Clinical evaluation of glycoPEGylated re-combinant FVIII: efficacy and safety in severe haemophilia A TrombHaemost. 2017:117(02):252 261.
Fischer K, lassila R. Peyvandi F, et al. inhibitor development in haemophilia according to concentrate. ThrombHaemost. 201S;l 14(4):670-675.
Lentz SR. Kavalki K. Klamroth R. et al. Turoctocog alpha pegol (NB,GP) in severe hemophilia A: long•term safety and efficacy in previously treated patients of all ages in the pathfinder8 study. Thromb Haemost. 2022;6(2):e12674.